Ulinastatin Analysis Service

Ulinastatin Analysis Service

Experience Enhanced Results: Trust CD BioGlyco for Ulinastatin Analysis Excellence!

CD BioGlyco is a leading company that specializes in the field of glycobiology, offering Pharmaceutical Analysis Services for clients all over the world. Specifically, we analyze various pharmaceuticals related to carbohydrates and their derivatives, such as ulinastatin. Ulinastatin is a glycoprotein extracted from fresh human urine that can inhibit the activity of various protein hydrolases. By suppressing various serine proteases and stabilizing lysosomes and cellular membranes, it exerts protective effects, reducing inflammation and decreasing both morbidity and mortality. We will conduct a comprehensive analysis of different formulations of ulinastatin, which include ulinastatin solution and ulinastatin for injection.

Fig.1 Applications of ulinastatin. (CD BioGlyco)Fig.1 Applications of ulinastatin. (CD BioGlyco)

Our ulinastatin analysis service contains an extensive range of key parameters for thorough pharmaceutical analysis.

  • Firstly, we accurately measure the molecular weight of the ulinastatin sample by advanced techniques such as mass spectrum. Through high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR), we conduct identification and content determination. This information is crucial for quality control purposes and ensures that the compound is within the desired specifications.
  • Subsequently, we conduct some evaluations of physical and chemical properties, including examining the clarity and color of solutions and evaluating the ion of acidity and alkalinity levels. We employ sophisticated analytical techniques to measure these factors accurately. It is vital to help clients ensure the optimal performance and stability of the ulinastatin compound.
  • Evaluation of hepatitis B surface antigen is also a vital part of ulinastatin analysis. Specialized assays and immunoassay techniques are utilized to detect the presence and quantity of hepatitis B surface antigens in the ulinastatin sample. This analysis is important to help clients ensure the safety and efficacy of the drug.
  • In addition, we assess the abnormal toxicity and the bacterial endotoxins of the ulinastatin sample to identify any potential risks or adverse effects associated with the compound.
  • Potency determination will be conducted through the use of ultraviolet (UV) visible spectrophotometry at CD BioGlyco.
  • Furthermore, we measure the content of heavy metals in the sample, including mercury (Hg), cadmium (Cd), arsenic (As), chromium (Cr), thallium (Tl), and lead (Pb). By analyzing those factors, we further help clients to ensure the safety and quality of the ulinastatin samples.

Fig.2 The factors we analyze for ulinastatin analysis service. (CD BioGlyco)Fig.2 The factors we analyze for ulinastatin analysis service. (CD BioGlyco)

Publication Data

Technology: Animal model

Journal: Frontiers in Physiology

IF: 4.0

Published: 2020

Results: In this study, authors explored the potential effects of ulinastatin, a potent anti-inflammatory agent, on decompression sickness (DCS) in a rabbit model. The study involved subjecting rabbits to simulated diving to 6 atmospheres absolute (ATA) for 60 minutes with subsequent decompression. Following decompression, three different doses of ulinastatin or saline were intravenously administered. Circulating bubbles were monitored, and ulinastatin signs were evaluated. Blood samples were collected and analyzed for various indices over a period of 72 hours post-decompression. The study found that the high dose of ulinastatin decreased mortality, general morbidity, and the incidence of severe DCS compared to the saline group. Ulinastatin also postponed the occurrence of DCS and prolonged survival time, as well as ameliorated inflammatory responses, endothelial injuries, and oxidative damage. The results indicated the potential benefit of ulinastatin in treating DCS, particularly in severe cases. Ulinastatin may be considered a promising pharmacological candidate for the treatment of severe DCS.


  • We possess extensive expertise and knowledge in pharmaceutical analysis, providing clients with the latest scientific insights and technical support.
  • We utilize advanced technologies and methods for pharmaceutical analysis and quality assessment to ensure the safety and efficacy of pharmaceuticals.
  • Our research team consists of outstanding scientists who have diverse academic backgrounds and expertise.

CD BioGlyco is a leading provider of pharmaceutical analysis and offers a comprehensive and rigorous assessment of various key factors for ulinastatin solution and ulinastatin for injection. Through expertise and advanced analytical techniques, we ensure the safety, quality, and efficacy of ulinastatin. If our analysis services meet your requirements, please contact us for a consultation.


  1. Meng, W.T.; et al. Ulinastatin: a potential alternative to glucocorticoid in the treatment of severe decompression sickness. Frontiers in Physiology. 2020, 11: 273.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.